Please login to the form below

Not currently logged in

CHMP 2019

This page shows the latest CHMP 2019 news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Lynparza in breast cancer, Dupixent in asthma

CHMP backs Lynparza in breast cancer, Dupixent in asthma

PARP inhibitor Lynparza (olaparib) – already making big headway in ovarian cancer – was given a positive opinion by the CHMP for BRCA-mutated, HER2-negative breast cancer, around a year after the ... Two rare diseases are on track to get their new

Latest news

  • Shire’s angioedema drug Takhzyro recommended in Europe Shire’s angioedema drug Takhzyro recommended in Europe

    The European Medicines Agency's CHMP committee has recommended Shire’s Takhzyro (lanadelumab), a new rare disease treatment which has blockbuster potential. ... Lanadelumab had been granted accelerated assessment by the EMA, which cut the evaluation

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...